Start here if you're new
what it is
Viatris sells branded and generic medicines in 165 countries to about 1 billion patients each year.
how it gets paid
Last year Viatris made $14.3B in revenue. Developed Markets was the main engine at $8.7B, or 61% of sales.
why growth slowed
Revenue fell 3.0% last year. The key number was $0.57 EPS, because beating by $0.01 shows stability but not real growth in a stock priced for skepticism.
what just happened
Latest quarterly earnings beat by a penny, with $0.57 EPS versus a $0.56 estimate.
At a glance
B++ balance sheet — above average — nothing keeping you up at night
100/100 earnings predictability — you can trust these numbers
5.0x trailing p/e — the market's not buying it — or you found a deal
4.5% dividend yield — cash in your pocket every quarter
11.5% return on capital — nothing to write home about
xvary composite: 68/100 — average
What they do
Viatris sells branded and generic medicines in 165 countries to about 1 billion patients each year.
Scale is the whole story here. Viatris sells medicines in 165 countries and reaches 1 billion patients a year, which gives your local pharmacy giant-volume suppliers to call first. Brands are 63% of 2024 sales versus 37% for generics, so you get both steadier legacy products and cheaper-volume drugs in one company.
How they make money
$14.3B
annual revenue · their business grew -3.0% last year
Developed Markets
$8.7B
Emerging Markets
$2.1B
Greater China
$2.1B
JANZ
$1.3B
The products that matter
global drug portfolio
Pharmaceutical portfolio
$14.3B revenue · 100% of sales
it's the whole $14.3B business, and it shrank 3.0% last year. that's why the stock looks cheap.
core
off-patent medicine platform
Generic Pharmaceuticals
2026 recovery case
the bull case depends on this business reaccelerating in 2026 while supporting company-wide earnings of $2.45 per share.
what has to work
established branded medicines
Branded Pharmaceuticals
margin support
these products sit inside a company that still earns a 19.3% net margin, but the snapshot does not break out segment profit. that's where the disclosure gets thin.
detail is thin
Key numbers
5.0x
trailing p/e
P/E → price-to-earnings → how many dollars you pay for $1 of profit. At 5.0x, the market is pricing in decline, not trust.
4.5%
dividend yield
Dividend yield → yearly cash payout as a share of stock price → what you get paid to wait. Viatris pays you more than many large drug stocks while you wait for proof.
$12.5B
long-term debt
Long-term debt → money owed over years → fixed obligations that do not care about your turnaround story. That debt stack is close to the company's roughly $13B market value.
11.5%
return on capital
Return on capital → profit from money invested in the business → whether management turns dollars into more dollars. 11.5% is decent, but not enough to erase shrinking sales by itself.
Financial health
B++
strength
- balance sheet grade B++ — above average financial health
- risk rank 3 — safer than 50% of stocks
- price stability 50 / 100
- long-term debt $12.5B (48% of capital)
- net profit margin 21.7% — keeps 22 cents of every dollar in revenue
- return on equity 16% — $0.16 profit for every $1 investors have put in
B++ — net profit margin looks solid but long-term debt needs watching.
Total return vs. market
You invested $10,000 in VTRS 3 years ago → it's now worth $12,010.
The index would have given you $13,920.
source: institutional data · total return
What just happened
beat estimates
Latest quarterly earnings beat by a penny, with $0.57 EPS versus a $0.56 estimate.
Revenue was $10.6B and gross margin was 36.6%, based on the latest reported quarter. The beat was tiny at 1.79%, so this was more relief than a real reset.
$10.6B
revenue
$0.57
eps
36.6%
gross margin
the number that mattered
The key number was $0.57 EPS, because beating by $0.01 shows stability but not real growth in a stock priced for skepticism.
-
viatris appears to be in the midst of a turnaround.
-
recent results have been pressured by import restrictions imposed by the u.s.fda last december, stemming from violations found during an inspection at the drugmaker’s indore facility. comparisons have also been weighed down by the impact of divestitures completed in 2024, which included substantially all of its over-the-counter (otc) business, its women’s healthcare division, and its active pharmaceutical ingredients (api) unit in india. that being said, several aspects of viatris’ core operations have exhibited strength of late, particularly the branded drug business in greater china and emerging markets. some stabilization in north america and europe, coupled with benefits from efficiency initiatives, have also been supportive of the bottom line. these factors have enabled the company to surpass consensus earnings expectations in each of the last two quarters.
-
we have raised our 2025 estimates.our projections now call for adjusted earnings to reach $2.35 a share this year on revenues of $14.15 billion, up from our previous forecasts of $2.25 and $13.90 billion. the revisions reflect recent strength in the underlying business, as well as a more favorable outlook in regard to foreign exchange.
-
despite the improvement, viatris is still looking at substantial top- and bottom-line declines in 2025.
-
our model calls for a partial earnings recovery in 2026.we anticipate a reacceleration in the generics business will occur next year, under the assumption of easing regulatory constraints. leadership’s cost-savings initiatives and benefits from recent business development deals, including its october acquisition of aculys pharma, also represent key catalysts.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is FDA import restrictions tied to the indore facility.
high
indore regulatory overhang
recent results were pressured by U.S. import restrictions tied to violations found during an FDA inspection at the indore facility.
this is already showing up in reported results, not just in theory.
med
the 2026 recovery may not arrive on schedule
the bull case leans on generics reaccelerating next year. if that recovery slips, a 3.0% revenue decline can keep looking structural instead of temporary.
cheap stocks stay cheap when growth never comes back.
med
debt reduces room for error
long-term debt is $12.5B, equal to 48% of capital. that is manageable, but it limits how forgiving the balance sheet can be if earnings wobble.
this is why the B++ balance sheet is good, not great.
low
cost savings have to become real earnings
management is leaning on cost-savings initiatives and recent business deals to support a partial 2026 rebound. if those gains stay on slides instead of in EPS, sentiment will stay stuck.
the market is waiting for proof, not another promise.
the recovery thesis sits on a business that already shrank 3.0% last year, posted -$0.11 EPS last quarter, and still carries $12.5B in long-term debt.
source: institutional data · regulatory filings · risk analysis
Pay attention to
risk
indore facility updates
if the FDA-related import restrictions ease, the entire recovery story gets cleaner fast. if they linger, the discount is probably justified.
metric
revenue stabilization
after a 3.0% annual decline, you want to see top-line erosion stop. flat is better than down. growth is the actual unlock for valuation.
trend
eps path into 2026
the $2.45 2026 EPS estimate is the number on trial. if quarterly earnings keep missing that path, the low multiple will not rerate.
calendar
next guidance reset
estimate revisions already moved 2025 to $2.35 EPS on $14.15B revenue. the next update tells you whether management is gaining credibility or borrowing time.
Analyst rankings
short-term outlook
top 20%
momentum score 2 — in human-speak, analysts think the stock can outperform over the next year even though the business still has work to do.
risk profile
average
stability score 3 — this sits in the middle of the pack on risk. not a bunker stock, not a disaster zone.
chart momentum
below average
technical score 4 — the chart says the market still needs convincing.
earnings predictability
100 / 100
guidance has been highly reliable. the irony is that predictable mediocre numbers are still mediocre numbers.
source: institutional data
Institutional activity
institutions have been net selling for 3 consecutive quarters — 400 buyers vs. 427 sellers in 3q2025. total institutional holdings: 1.0B shares. net selling for 3 quarters.
source: institutional data
Price targets
3-5 year target range
$7
$15
$12
current price
$11
target midpoint · 6% from current · 3-5yr high: $20 (+70% · 16% ann'l return)
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive